Charles Elliott Sigal, Director at Adaptimmune Therapeutics PLC (ADAP), bought 45,000 shares at $1.53 ($69K) on 2016-05-17, disclosed to the SEC on 2016-05-18.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.50 | 15,000 | $23K | 32.8% |
| 2 | $1.53 | 15,000 | $23K | 33.4% |
| 3 | $1.55 | 15,000 | $23K | 33.8% |
| Total | $1.53 avg | 45,000 | $69K | 100% |
| Filing → |
| VIR | BUY | 2023-01-05 | $127K | — | Filing → |
| ADAP | BUY | 2016-05-19 | $23K | — | Filing → |